AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24784420 — intervention group
Group type: EXPERIMENTAL
Intervention: GC test as a risk factor
Number of subjects: 145
Study 24784420 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of GC test results
Number of subjects: 145
Study 23567146 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab, lapatinib, or their combination with paclitaxel before surgery
Number of subjects: 429
Study 23567146 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 429
Study 21118833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saving system (CS) (n=34)
Number of subjects: 63
Study 21118833 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO) (n=29)
Number of subjects: 63
Study 21118833 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell saving system (CS)
Number of subjects: 63
Study 21118833 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 63
Study 20047724 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cognitive-behavioral therapy (CBT) for OCD
Number of subjects: 29
Study 20047724 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated cognitive-behavioral therapy (CBT) focusing on MDD in the first phase and OCD in the second phase
Number of subjects: 29
Study 17089228 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg dexketoprofen
Number of subjects: 50
Study 17089228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 15612853 — intervention group
Group type: EXPERIMENTAL
Intervention: Addiction treatments (specifics not provided)
Number of subjects: 1726
Study 11567541 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (paracetamol)
Number of subjects: 0
Study 11567541 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 0
Study 11567541 — intervention group
Group type: EXPERIMENTAL
Intervention: Coxibs (COX-2-specific inhibitors)
Number of subjects: 0
Study 11567541 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin sulphate, diacerhein, glucosamine sulphate
Number of subjects: 0
Study 11567541 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulphate
Number of subjects: 0
Study 11567541 — intervention group
Group type: EXPERIMENTAL
Intervention: Diacerhein
Number of subjects: 0
Study 9258859 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB 30 mg/kg
Number of subjects: 8
Study 9258859 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8355645 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early treatment group (ET Gr)
Number of subjects: 84
Study 8355645 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge treatment group (PDT Gr)
Number of subjects: 84
Study 8355645 — intervention group
Group type: COMPARATOR
Intervention: Control group (C Gr)
Number of subjects: 84
Study 3300841 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplements (48 mmol daily)
Number of subjects: 37
Study 3300841 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplements (24 mmol daily) in a subgroup of 13 patients
Number of subjects: 37
Study 3300841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 30089798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 300 mg twice daily for 8 weeks
Number of subjects: 19
Study 30089798 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 400 IU twice daily for 8 weeks
Number of subjects: 19
Study 26908418 — intervention group
Group type: EXPERIMENTAL
Intervention: V.A.C. therapy
Number of subjects: 18
Study 26908418 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 18
Study 26908418 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 18
Study 25183304 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 78
Study 25183304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 24359572 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriatic-cocktail soaked sponge (group 1)
Number of subjects: 0
Study 24359572 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional eyedrop regimen (group 2)
Number of subjects: 0
Study 24359572 — intervention group
Group type: COMPARATOR
Intervention: Mydriatic sponge (group 3, control group)
Number of subjects: 0
Study 20796178 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted exercise (5 days a week for 4 weeks)
Number of subjects: 16
Study 20796178 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 16
Study 17851535 — intervention group
Group type: COMPARATOR
Intervention: Intranasal methamphetamine 0 mg/70 kg
Number of subjects: 11
Study 17851535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine 12 mg/70 kg
Number of subjects: 11
Study 17851535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine 25 mg/70 kg
Number of subjects: 11
Study 17851535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal methamphetamine 50 mg/70 kg
Number of subjects: 11
Study 15866571 — intervention group
Group type: EXPERIMENTAL
Intervention: P and 2 mg of E2
Number of subjects: 166
Study 15866571 — intervention group
Group type: EXPERIMENTAL
Intervention: P and 6 mg of E2
Number of subjects: 166
Study 15866571 — intervention group
Group type: COMPARATOR
Intervention: P only (no E2)
Number of subjects: 166
Study 12419088 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy (Climara, 50 microg 17beta‐estradiol for 3 months)
Number of subjects: 0
Study 10321673 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual ventilation during transport
Number of subjects: 49
Study 10321673 — intervention group
Group type: COMPARATOR
Intervention: Mechanical ventilation by a portable ventilator
Number of subjects: 49
Study 7862384 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-g GTT
Number of subjects: 80
Study 7862384 — intervention group
Group type: COMPARATOR
Intervention: 50-g GTT
Number of subjects: 80
Study 7862384 — intervention group
Group type: COMPARATOR
Intervention: 75-g GTT
Number of subjects: 80
Study 1936482 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed-time NPH insulin (0.2 U/Kg)
Number of subjects: 12
Study 1936482 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg x 3)
Number of subjects: 12
Study 6818269 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sodium cromoglycate collyre
Number of subjects: 143
Study 6818269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 31981712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth care with home BP telemonitoring and management by a clinical pharmacist
Number of subjects: 21
Study 31981712 — intervention group
Group type: COMPARATOR
Intervention: Best-practice clinic-based care
Number of subjects: 21
Study 31981712 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth care
Number of subjects: 21
Study 30428930 — intervention group
Group type: EXPERIMENTAL
Intervention: 23.4% NaCl
Number of subjects: 0
Study 30428930 — intervention group
Group type: EXPERIMENTAL
Intervention: 16.4% NaCl/Na-Acetate
Number of subjects: 0
Study 25265004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aqueous suppression therapy (β‐blockers, α‐agonists, or carbonic anhydrase inhibitors) initiated when postoperative IOP >10 mm Hg (low‐IOP initiation group)
Number of subjects: 50
Study 25265004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aqueous suppression therapy (β‐blockers, α‐agonists, or carbonic anhydrase inhibitors) initiated when postoperative IOP >17 mm Hg (moderate‐IOP initiation group)
Number of subjects: 50
Study 25265004 — intervention group
Group type: EXPERIMENTAL
Intervention: Early aqueous suppression therapy (initiated before HP onset)
Number of subjects: 50
Study 25265004 — intervention group
Group type: COMPARATOR
Intervention: Eyes with HP
Number of subjects: 50
Study 25265004 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐IOP initiation group
Number of subjects: 50
Study 25265004 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy initiated after HP onset
Number of subjects: 50
Study 23873699 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular bone score (TBS)
Number of subjects: 665
Study 23873699 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TBS and aBMD
Number of subjects: 665
Study 23873699 — intervention group
Group type: EXPERIMENTAL
Intervention: TBS
Number of subjects: 665
Study 22738148 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 100
Number of subjects: 52
Study 22738148 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/VI 100/25
Number of subjects: 52
Study 22738148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 22738148 — intervention group
Group type: EXPERIMENTAL
Intervention: FF 100 vs FF/VI 100/25
Number of subjects: 52
Study 20479673 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt insertion during CEA
Number of subjects: 57
Study 20479673 — intervention group
Group type: COMPARATOR
Intervention: Regional anesthesia
Number of subjects: 57
Study 20479673 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 57
Study 20479673 — intervention group
Group type: COMPARATOR
Intervention: No shunt insertion
Number of subjects: 57
Study 18773327 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide 200 mcg
Number of subjects: 100
Study 18773327 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone 125 mcg
Number of subjects: 100
Study 18773327 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide and fluticasone (both used on different occasions)
Number of subjects: 100
Study 18773327 — intervention group
Group type: COMPARATOR
Intervention: 4-day treatment protocol
Number of subjects: 100
Study 18773327 — intervention group
Group type: COMPARATOR
Intervention: 8-day treatment protocol
Number of subjects: 100
Study 18773327 — intervention group
Group type: COMPARATOR
Intervention: 8-day treatment protocol + azithromycin
Number of subjects: 100
Study 15742421 — intervention group
Group type: EXPERIMENTAL
Intervention: Killing Hp quadruple therapy (group B: lansoprazole 30 mg qd, clarithromycin 250 mg bid, amoxycillin 500 mg tid for 10 d, plus killing H pylori capsule 6 capsules bid for 4 wk)
Number of subjects: 75
Study 15742421 — intervention group
Group type: EXPERIMENTAL
Intervention: New triple therapy (group A: lansoprazole 30 mg qd, clarithromycin 250 mg bid, amoxycillin 500 mg tid for 10 d)
Number of subjects: 75
Study 15742421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C: gastropine 3 tablets bid for 4 wk)
Number of subjects: 75
Study 15742421 — intervention group
Group type: EXPERIMENTAL
Intervention: Killing Hp quadruple therapy (group B)
Number of subjects: 75
Study 15742421 — intervention group
Group type: EXPERIMENTAL
Intervention: New triple therapy (group A)
Number of subjects: 75
Study 15742421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 75
Study 12023699 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized magnesium sulfate (384 mg in 6 mL of sterile water) plus albuterol (2.5 mg/3 mL)
Number of subjects: 74
Study 12023699 — intervention group
Group type: COMPARATOR
Intervention: Albuterol (2.5 mg/3 mL) alone
Number of subjects: 74
Study 10754431 — intervention group
Group type: EXPERIMENTAL
Intervention: isopolicosanol (3.6 mg/die for 7 days)
Number of subjects: 30
Study 10754431 — intervention group
Group type: EXPERIMENTAL
Intervention: octacosanol (3.6 mg/die for 7 days)
Number of subjects: 30
Study 10754431 — intervention group
Group type: COMPARATOR
Intervention: placebo (group A)
Number of subjects: 30
Study 8867776 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt depletion (SD) with low sodium chloride dietary intake (< or = 60 mmol per day) and combined treatment with natriuretic and potassium sparing drugs
Number of subjects: 8
Study 8867776 — intervention group
Group type: COMPARATOR
Intervention: Enalapril treatment in the SD group
Number of subjects: 8
Study 8867776 — intervention group
Group type: EXPERIMENTAL
Intervention: LVP low-dose infusion during hypotonic polyuria
Number of subjects: 8
Study 8867776 — intervention group
Group type: COMPARATOR
Intervention: Salt depletion (SD) vs. normal sodium and potassium balance (N3, n = 6)
Number of subjects: 8
Study 1385778 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (ISR)
Number of subjects: 198
Study 1385778 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside (SNP)
Number of subjects: 198
Study 6743784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine formulation A
Number of subjects: 24
Study 6743784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine formulation B
Number of subjects: 24
Study 30520208 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment combined with lifestyle intervention (Weight Watchers)
Number of subjects: 0
Study 30520208 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention alone (placebo)
Number of subjects: 0
Study 29227727 — intervention group
Group type: EXPERIMENTAL
Intervention: ELLIPTA inhaler
Number of subjects: 212
Study 29227727 — intervention group
Group type: COMPARATOR
Intervention: HandiHaler inhaler
Number of subjects: 212
Study 26865390 — intervention group
Group type: COMPARATOR
Intervention: BTH1677 at 0.5, 1, 2, 4, or 6 mg/kg (Phase 1a)
Number of subjects: 36
Study 26865390 — intervention group
Group type: COMPARATOR
Intervention: BTH1677 at 1, 2, or 4 mg/kg (Phase 1b)
Number of subjects: 36
Study 24618964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrospinous ligament fixation (SSLF)
Number of subjects: 374
Study 24618964 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (ULS)
Number of subjects: 374
Study 24618964 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative behavioral therapy with pelvic floor muscle training (BPMT)
Number of subjects: 374
Study 24618964 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 374
Study 23234350 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard adherence intervention package plus structured three session group intervention
Number of subjects: 152
Study 23234350 — intervention group
Group type: COMPARATOR
Intervention: Standard adherence intervention package alone
Number of subjects: 152
Study 23234350 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (intervention and control)
Number of subjects: 152
Study 23234350 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker intervention
Number of subjects: 152
Study 20479363 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback intervention in experimental hospitals
Number of subjects: 1211
Study 20479363 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospitals without performance feedback)
Number of subjects: 1211
Study 18705725 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-oriented discharge planning program (experimental group, n = 72 dyads)
Number of subjects: 158
Study 18705725 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital discharge planning services (control group, n = 86 dyads)
Number of subjects: 158
Study 18705725 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-oriented discharge planning program (experimental group)
Number of subjects: 158
Study 18705725 — intervention group
Group type: COMPARATOR
Intervention: Routine hospital discharge planning services (control group)
Number of subjects: 158
Study 15918131 — intervention group
Group type: EXPERIMENTAL
Intervention: Beginners
Number of subjects: 15
Study 15918131 — intervention group
Group type: COMPARATOR
Intervention: Experienced and professional runners
Number of subjects: 15
Study 12887355 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy training (12 sessions)
Number of subjects: 62
Study 12887355 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 62
Study 10636315 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric self-inflating bag with laryngeal mask airway
Number of subjects: 16
Study 10636315 — intervention group
Group type: COMPARATOR
Intervention: Adult self-inflating bag with laryngeal mask airway
Number of subjects: 16
Study 10636315 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric self-inflating bag with combitube
Number of subjects: 16
Study 10636315 — intervention group
Group type: COMPARATOR
Intervention: Adult self-inflating bag with combitube
Number of subjects: 16
Study 10636315 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric self-inflating bag with bag-valve-face mask
Number of subjects: 16
Study 10636315 — intervention group
Group type: COMPARATOR
Intervention: Adult self-inflating bag with bag-valve-face mask
Number of subjects: 16
Study 10636315 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 16
Study 10636315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 16
Study 8548891 — intervention group
Group type: COMPARATOR
Intervention: Aspirin therapy alone
Number of subjects: 226
Study 8548891 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine and aspirin therapy
Number of subjects: 226
Study 1824790 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (goserelin acetate implant)
Number of subjects: 240
Study 1824790 — intervention group
Group type: COMPARATOR
Intervention: Castration
Number of subjects: 240
Study 1824790 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum testosterone levels
Number of subjects: 240
Study 1824790 — intervention group
Group type: COMPARATOR
Intervention: Serum testosterone levels < 6.9 nmol/L
Number of subjects: 240
Study 6431462 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 0
Study 6431462 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxapine
Number of subjects: 0
Study 6431462 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline and Amoxapine
Number of subjects: 0
Study 31519975 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterjet dissection
Number of subjects: 60
Study 31519975 — intervention group
Group type: COMPARATOR
Intervention: Control (blunt dissection)
Number of subjects: 60
Study 30373539 — intervention group
Group type: EXPERIMENTAL
Intervention: Tighter glycaemic targets (fasting plasma glucose ≤5.0 mmol/L, 1 h postprandial ≤7.4 mmol/L, 2 h postprandial ≤6.7 mmol/L)
Number of subjects: 1080
Study 30373539 — intervention group
Group type: COMPARATOR
Intervention: Less tight glycaemic targets (fasting plasma glucose < 5.5 mmol/L; 1 h postprandial < 8.0 mmol/L; 2 h postprandial < 7.0 mmol/L)
Number of subjects: 1080
Study 26438533 — intervention group
Group type: EXPERIMENTAL
Intervention: S-flurbiprofen plaster (SFPP) 20 mg applied for 12 hours
Number of subjects: 0
Study 26438533 — intervention group
Group type: EXPERIMENTAL
Intervention: S-flurbiprofen plaster (SFPP) 2-60 mg applied for 24 hours
Number of subjects: 0
Study 26438533 — intervention group
Group type: COMPARATOR
Intervention: Commercially available flurbiprofen (FP) gel-type patch
Number of subjects: 0
Study 24268189 — intervention group
Group type: EXPERIMENTAL
Intervention: Volar locking plate fixation
Number of subjects: 152
Study 24268189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation
Number of subjects: 152
Study 21919646 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based prostate cancer screening decision aid
Number of subjects: 531
Study 20410771 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 149
Study 20410771 — intervention group
Group type: EXPERIMENTAL
Intervention: Promethazine
Number of subjects: 149
Study 17824582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with tretinoin microsphere (RAM) gel 0.04%
Number of subjects: 0
Study 17824582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with tretinoin microsphere (RAM) gel 0.1%
Number of subjects: 0
Study 17824582 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel with adapalene (AP) gel 0.1%
Number of subjects: 0
Study 17824582 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy of clindamycin 1%-benzoyl peroxide (BPO) 5% topical gel
Number of subjects: 0
Study 17008436 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake before (approximately 150 g) and during exercise (1 g.kg body weight(‐1).h(‐1))
Number of subjects: 8
Study 17008436 — intervention group
Group type: COMPARATOR
Intervention: Overnight fast (F)
Number of subjects: 8
Study 17008436 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate intake (CHO) and fasting (F)
Number of subjects: 8
Study 15520102 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 85
Study 15520102 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 85
Study 11676382 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 13
Study 9306083 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk with DHA concentrations that ranged from 0.1‐1.7% of total fatty acids
Number of subjects: 52
Study 8308768 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet
Number of subjects: 12
Study 8308768 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution
Number of subjects: 12
Study 8308768 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (sc) injection
Number of subjects: 12
Study 8308768 — intervention group
Group type: COMPARATOR
Intervention: Oral tablet vs Oral solution
Number of subjects: 12
Study 3030386 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 13
Study 3030386 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg
Number of subjects: 13
Study 3030386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31792949 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone 5 μg.kg‐1.h‐1 infusion
Number of subjects: 95
Study 31792949 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 95
Study 31300019 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncut Roux-en-Y anastomosis
Number of subjects: 832
Study 31300019 — intervention group
Group type: COMPARATOR
Intervention: Billroth II anastomosis
Number of subjects: 832